Clinical Trial Search

Primary: Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response — 114; 109; 106; 50 Participants — p=0.39

Primary: Number of Participants With the Development of Hepatocellular Carcinoma (HCC) — 15; 11 Participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 70; 35 participants

Primary: Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks — -1.75; -1.38 percentage of glycosylated hemoglobin…

Primary: Change in Hemoglobin Concentration in Grams Per Deciliter (g/dL) From Baseline to the Average of the Last 12 Weeks of Treatment — -0.02; -0.10; -0.19 g/dL

Primary: Responders Based Upon the Timed 25-Foot Walk [T25FW] — 51; 11 participants

Primary: Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero — 35.5; 46.8; 11.8 Percentage of Patients

Primary: Response Rate (Clinical Response, Data Review Committee Assessment) — 86.3; 84.5; 82.9 percentage of participants

Primary: Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy — 2.5; 5.6 units on a scale

Primary: Cumulative Percentage of Participants by Heavy Drinking Rate — 40.8; 47.3; 59.2; 59.5 percentage of participants — p=0.336

Primary: Overall Discrepancy Rate — 0.13 Overall discrepancies per 100 actuations

Primary: Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8] — 167.9; 193.2; 171.0; 9.3 dilution units — p=<0.001

Primary: Time to Recovery of the T4/T1 Ratio to 0.9. — 205; 112 seconds

Primary: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — 8.08; 8.07; 7.98; 8.06 percentage of glycosylated hemoglobins — p=<.0001

Primary: Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population — -54.1; -62.0; -54.5 Change in Hot Flush Count